DOCSLIB.ORG

1111111111111111111Imnumu

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://ntrs.nasa.gov/search.jsp?R=20150007181 2019-08-31T10:47:26+00:00Z 1111111111111111111imnumu (12) United States Patent (1o) Patent No.: US 9,005,185 B2 Ferrari et al. (45) Date of Patent: Apr. 14, 2015 (54) NANOCHANNELED DEVICE AND RELATED (52) U.S. Cl. METHODS CPC .............. A61M37/00(2013.01);A61K910097 (2013.01); B81C1100119 (2013.01); B82Y5100 (71) Applicants: The Board of Regents of the University (2013.01); A61M 5114276 (2013.01); B81B of Texas System, Austin, TX (US); The 22011058 (2013.01); B81B 220310338 Ohio State University Research (2013.01) Foundation, Columbus, OH (US) (58) Field of Classification Search CPC . A61M 5/14276; A61M 5/141; A61M 37/00; (72) Inventors: Mauro Ferrari, Houston, TX (US); A61 M 2209/045; A61 M 2039/0264; A61 M 2039/0291; A61F 2250/0068; A61K 9/0097; Xuewu Liu, Sugar Land, TX (US); 138113 2201/058; 138113 2203/0338 Alessandro Grattoni, Houston, TX USPC ........ 604/246, 288.01, 288.02, 288.04, 891.1 (US); Randy Goodall, Austin, TX (US); See application file for complete search history. Lee Hudson, Elgin, TX (US) (56) References Cited (73) Assignees: The Board of Regents of the University of Texas System, Austin, TX (US); The U.S. PATENT DOCUMENTS Ohio State University Research Foundation, Columbus, OH (US) 3,731,681 A 5/1973 Blackshear et al. 3,921,636 A 11/1975 Zaffaroni (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/099,429 DE 10 2006 014476 7/2007 EP 1 977 775 10/2008 (22) Filed: Dec. 6, 2013 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2014/0180251 Al Jun. 26, 2014 "The Economic Costs of Drug Abuse in the United States," www. whitehousedrugpolicy.gov, Sep. 2001. (Continued) Related U.S. Application Data (63) Continuation of application No. 13/264,069, filed as Primary Examiner Nicholas Lucchesi application No. PCT/US2010/030937 on Apr. 13, Assistant Examiner Gerald Landry, II 2010, now Pat. No. 8,632,510, which is a (74) Attorney, Agent, or Firm Parker Highlander PLLC (Continued) (57) ABSTRACT (51) Int. Cl. A capsule configured for in vivo refilling of a therapeutic A61K9122 (2006.01) agent. In certain embodiments, the capsule may contain A61M37100 (2006.01) methotrexate. (Continued) 14 Claims, 39 Drawing Sheets 636 1624 11 .- 1634 1616 11 , 1 626 1650 1614 1613 1 '1 1602 1600 US 9,005,185 B2 Page 2 Related U.S. Application Data OTHER PUBLICATIONS "Under the Counter: The Diversion and Abuse of Controlled Pre- continuation-in-part of application No. 12/618,233, scription Drugs in the US," The National Center on Addiction and filed on Nov. 13, 2009, now Pat. No. 8,480,637. Substance Abuse (CASA) at Columbia University, New York, NY, (60) Provisional application No. 61/168,844, filed on Apr. CASA, Jul. 2005. 13, 2009, provisional application No. 61/114,687, Christensen et al., "Tantalum oxide thin films as protective coatings filed on Nov. 14, 2008. for sensors," J. Micromech. Microeng., 9:113-118, 1999. Extended European Search Report issued in European Application (51) Int. Cl. No. 10765046, mailed Oct. 1, 2012. A61K9/00 (2006.01) Extended European Search Report issued in European Application B81C1/00 (2006.01) No. 09826831, mailed Jul. 12, 2012. B82Y5100 (2011.01) Fine et al., "A robust nanofiuidic membrane with tunable zero-order release for implantable dose specific drug delivery," Lab on a Chip, A61M51142 (2006.01) 10(2): 3074-3083, 2010. Hammerle et al., `Biostability of micro-photodiode arrays for (56) References Cited subretinal implantation," Biomaterials., 23:797-804, 2002. U.S. PATENT DOCUMENTS Hess et al., "PECVD silicon carbide as athin filmpackaging material for microfabricated neural electrodes," Mater. Res. Soc. Symp. Proc., 4,834,704 A 5/1989 Reinicke 1009-U04-03, 2007. 4,955,861 A 9/1990 Enegren et al. Narayan et al., "Mechanical and biological properties of nanoporous 5,085,656 A * 2/1992 Polaschegg ............. 604/891.1 carbon membranes," Biomed. Mater., 3:034107, 2008. 5,395,324 A 3/1995 Hinrichs et al. Nath et al., `Buprenorphine pharmacokinetics: relative bioavail- 5,651,900 A 7/1997 Keller et al. ability of sublingual tablet and liquid formulations," J Clin. 5,728,396 A 3/1998 Peery et al. 5,769,823 A 6/1998 Otto Pharmacol., 39:619-623, 1999. 5,770,076 A 6/1998 Chu et al. Nurdin et al., "Haemocompatibility evaluation of DLC-and SIC- 5,798,042 A 8/1998 Chu et al. coated surfaces," Ear Cells Mat., 5: 17-28, 2003. 5,893,974 A 4/1999 Keller et al. Office Action issued in European Application No. 09826831, mailed 5,938,923 A 8/1999 Tu et al. Jul. 11, 2013. 5,948,255 A 9/1999 Keller et al. Office Action issued in European Application No. 10765046, mailed 5,985,164 A 11/1999 Chu etal. Jul. 11, 2013. 5,985,328 A 11/1999 Chu et al. 6,044,981 A 4/2000 Chu et al. Office Action issued in U.S. Appl. No. 12/618,233, mailed Oct. 16, 6,592,519 B1 7/2003 Martinez 2012. 7,025,871 132 4/2006 Broadley et al. Office Action issued in U.S. Appl. No. 13/264,069, mailed Feb. 22, 7,135,144 132 11/2006 Christel et al. 2013. 7,326,561 132 * 2/2008 Goodman et al. ...... 435/286.5 Office Action issued in U.S. Appl. No. 13/264,069, mailed Oct. 29, 7,955,614 132 6/2011 Martin et al. 2012. 2002/0087120 Al 7/2002 Rogers et al. 2002/0156462 Al 10/2002 Stultz PCT International Search Report and Written Opinion issued in 2003/0010638 Al 1/2003 Hansford et al. International Application No. PCT/US2011/037094, dated Jan. 13, 2003/0064095 Al 4/2003 Martin et al. 2012. 2 004/003 82 60 Al 2/2004 Martin et al. PCT International Search Report and Written Opinion issued in 2004/0082908 Al 4/2004 Whitehurst et al. International Application No. PCT/US2010/030937, dated Feb. 21, 2004/0116905 Al 6/2004 Pedersen et al. 2011. 2004/0260418 Al * 12/2004 Staats ..................... 700/97 PCT International Search Report and Written Opinion issued in 2004/0262159 Al 12/2004 Martin et al. 2005/0118229 Al 6/2005 Boiarski International Application No. PCT/US2009/064376, mailedAug.23, 2006/0180469 Al* 8/2006 Han et al ................. 204/601 2010. 2006/0191831 Al 8/2006 Hansford et al. Report: Stakeholder Workshop on a National Buprenorphine Pro- 2006/0259015 Al * 11/2006 Steinbach ............... 604/891.1 gram, Health Canada, Nov. 18, 2004. 2006/0270983 Al* 11/2006 Lord et al . .............. 604/131 Samhsa, "Overview of Findings from the 2002 National Survey on 2007/0066138 Al 3/2007 Ferrari et al. Drug Use and Health," Rockville, MD, DHHS publication, SMA 2007/0077273 Al* 4/2007 Martin et al. ........... 424/423 03-3774. 2007/0286773 Al* 12/2007 Schlautmann et al. 422/68.1 2008/0073506 Al 3/2008 Lazar Samhsa, "Results from the 2003 National Survey on Drug Use and 2 009/02 143 92 Al 8/2009 Kameoka et al. Health: National Findings," Rockeville, MD, DHHS publication, 2010/0152699 Al 6/2010 Ferrari et al. SMA 04-3964. 2011/0137596 Al 6/2011 Grattoni et al. Samhsa, "The Dawn Report: oxycodaone, hydrocodone, and polydrug use," 2002. Jul. 2004 http://oas.samhsa.gov/2k4/ FOREIGN PATENT DOCUMENTS oxycodone/oxycodone.cfm. Schmitt et al., "Passivation and corrosion of microelctrode arrays," WO WO 00/74751 12/2000 Electrochimica Acta, 44:3865-3883, 1999. WO WO 2004/036623 4/2004 Voskerician et al., `Biocompatibility and biofouling of MEMS drug WO WO 2005/079387 9/2005 delivery devices," Biomaterials, 24:1959-1967, 2003. WO WO 2006/113860 10/2006 Yakimova et al., "Surface functionalization and biomedical applica- WO WO 2007/047539 4/2007 tions base on SiC,"JPhysics D, 40: 6435- 6442, 2007. WO WO 2007/089483 8/2007 WO WO 2008/019886 9/2008 Zorman et al., "Silicon carbide as a material for biomedical WO WO 2009/149362 12/2009 Microsystems," DIT, Apr. 1-3, 2009. WO WO 2010/056986 5/2010 WO WO 2010/120817 10/2010 * cited by examiner U.S. Patent Apr. 14, 2015 Sheet 1 of 39 US 9,005,185 B2 *i M 3'`C~~ `✓ _ 7 i ;i Q V-ft ^ep~Paad C6: e °pia Nz F~ 11 1 l cm iz °ape 3 3j1> i U- 1 U.S. Patent Apr. 14 , 2015 Sheet 2 of 39 US 9,005,185 B2 10 15 FIG. 2A 10 --"~ 15 " P~ 25 F1.2 U.S. Patent Apr. 14, 2015 Sheet 3 of 39 US 9,005,185 B2 10 15 25 FIG. 2C 25 20 FIG. 2D U.S. Patent Apr. 14, 2015 Sheet 4 of 39 US 9,005,185 B2 25 20 FIG. 2E U.S. Patent Apr. 14, 2015 Sheet 5 of 39 US 9,005,185 B2 FIG. 3B FIG. 3C U.S. Patent Apr. 14, 2015 Sheet 6 of 39 US 9,005,185 B2 of 60 70 25 20 40 F1.3 U.S. Patent Apr. 14, 2015 Sheet 7 of 39 US 9,005,185 B2 20 *-40 FIG. 3E 20 FIG. 3F U.S. Patent Apr. 14, 2015 Sheet 8 of 39 US 9,005,185 B2 FIG. 3G U.S. Patent Apr. 14, 2015 Sheet 9 of 39 US 9,005,185 B2 3 cm a i - u r µ t' r CZ CI ! i`3t kti1 j~ I X } } .
Recommended publications
  • Clinical Evaluation of Pipecuronium Bromide and Its Comparison With

    Clinical Evaluation of Pipecuronium Bromide and Its Comparison With

    Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch. J. App. Med. Sci., 2013; 1(6):943-950 ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com Research Article Clinical Evaluation of Pipecuronium Bromide and its Comparison with Pancuronium Bromide Kaushal RP Associate Professor, Department of cardiac anesthesia, Gandhi Medical College, Bhopal, India. *Corresponding author Kaushal RP Email: Abstract: The study was carried out to compare the intubating conditions, cardiovascular responses, neuro-muscular blocking properties and reversal characteristics of pipecuronium bromide and pancuronium bromide. This is a prospective hospital based study. 100 patients belonging to ASA grade I or II physical status aged 18 to 70 years were divided into two groups of 50 patients each. Group 1 received pipecuronium bromide in the dose of .08 mg / kg and group 2 patients received pancuronium bromide in dose of 0.1 mg/kg. Each patient was pre medicated uniformly. Time for onset of apnoea for pipecuronium and pancuronium were 91.64+ 3.59 sec. and 118.84 + 12.53 sec. respectively. The mean time for intubation was 126.60 +12.55 sec. and 144.60 + 22.87 sec. with pipecuronium and pancuronium respectively. Mean duration of block for pipecuronium was 78.64 + 8.97 min. the block for pancuronium lasted from +36-40 min with a mean duration of block 41.60+ 5.57 min. The mean duration of maintenance dose in pipecuronium cases was 45.08 + 7.19 min., while it was 27.06 + 5.01 min in pancuronium cases.
  • Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: a Randomized Trial

    Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: a Randomized Trial

    RESEARCH REPORT Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial Edömér Tassonyi, MD, PhD, DSc, Adrienn Pongrácz, MD, Réka Nemes, MD, László Asztalos, MD, Szabolcs Lengyel, PhD, DSc, and Béla Fülesdi, MD, PhD, Dsc * * * * BACKGROUND: Pipecuronium† is a steroidal neuromuscular* blocking agent. Sugammadex, a relaxant binding γ-cyclodextrin derivative, reverses the effect of rocuronium, vecuronium, and pancuronium. We investigated whether sugammadex reverses moderate pipecuronium-induced neuromuscular blockade (NMB) and the doses required to achieve reversal. METHODS: This single-center, randomized, double-blind, 5-group parallel-arm study comprised 50 patients undergoing general anesthesia with propofol, sevoflurane, fentanyl, and pipe- curonium. Neuromuscular monitoring was performed with acceleromyography (TOF-Watch SX®) according to international standards. When the NMB recovered spontaneously to train-of-four count 2, patients randomly received 1.0, 2.0, 3.0, or 4.0 mg/kg of sugammadex or placebo. Recovery time from sugammadex injection to normalized train-of-four (TOF) ratio 0.9 was the primary outcome variable. The recovery time from the sugammadex injection to final T1 was the secondary end point. Postoperative neuromuscular functions were also assessed. RESULTS: Each patient who received sugammadex recovered to a normalized TOF ratio of 0.9 within 5.0 minutes (95% lower confidence interval for the lowest dose 70.1%; for all doses 90.8%) and 79% of these patients reached a normalized TOF ratio 0.9 within 2.0 minutes (95% lower confidence interval for the lowest dose 26.7%; for all doses 63.7%). T1 recovered several minutes after the TOF ratio.
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al

    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication

    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor

    Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor

    molecules Article Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor Tim J. Fyfe 1, Peter J. Scammells 1, J. Robert Lane 2,3,* and Ben Capuano 1,* 1 Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; tim.fyfe@griffithhack.com (T.J.F.); [email protected] (P.J.S.) 2 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia 3 School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK * Correspondence: [email protected] (J.R.L.); [email protected] (B.C.) Abstract: (1) Background: Two first-in-class racemic dopamine D1 receptor (D1R) positive allosteric modulator (PAM) chemotypes (1 and 2) were identified from a high-throughput screen. In particular, due to its selectivity for the D1R and reported lack of intrinsic activity, compound 2 shows promise as a starting point toward the development of small molecule allosteric modulators to ameliorate the cognitive deficits associated with some neuropsychiatric disease states; (2) Methods: Herein, we describe the enantioenrichment of optical isomers of 2 using chiral auxiliaries derived from (R)- and (S)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one (D- and L-pantolactone, respectively); (3) Results: We confirm both the racemate and enantiomers of 2 are active and selective for the D1R, but that the respective stereoisomers show a significant difference in their affinity and magnitude of positive allosteric cooperativity with dopamine; (4) Conclusions: These data warrant further investigation Citation: Fyfe, T.J.; Scammells, P.J.; of asymmetric syntheses of optically pure analogues of 2 for the development of D1R PAMs with Lane, J.R.; Capuano, B.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol